• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dyadic International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    5/5/25 5:03:31 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DYAI alert in real time by email
    dyai20250504_8k.htm
    false 0001213809 0001213809 2025-05-01 2025-05-01
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    FORM 8-K
     

     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    Date of Report (date of earliest event reported): May 1, 2025
     

     
    Dyadic International, Inc.
    (Exact name of registrant as specified in its charter)
     

     
    Delaware 000-55264 45-0486747
    (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification Number)
     
    1044 North U.S. Highway One, Suite 201
    Jupiter, FL 33477
    (Address of principal executive offices and zip code)
     
    (561) 743-8333
    (Registrant’s telephone number, including area code)
     
    N/A
    (Former Name or Former Address, if Changed Since Last Report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act
     
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, par value $0.001 per share
    DYAI
    The Nasdaq Stock Market LLC
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     

     
     
    Item 1.01.         Entry into a Material Definitive Agreement.
     
    On May 1, 2025, Dyadic International, Inc. (the “Company”) entered into a second amendment (the “Second Amendment”) to the Form of Senior Secured Convertible Promissory Note due March 8, 2027 (the “Convertible Notes”) with a majority of the current holders of the Convertible Notes. Pursuant to the Second Amendment, the Redemption Date (as defined in the Second Amendment) now will fall on December 1, 2026.
     
    The foregoing description of the Second Amendment is only a summary of the material terms thereof, does not purport to be complete and is qualified in its entirety by reference to the full text of the Second Amendment, a copy of which is attached as Exhibit 4.1 to this Current Report on Form 8-K and is incorporated herein by reference.
     
    Item 9.01.         Financial Statements and Exhibits.
     
    (d) Exhibits
     
    Exhibit
    Number
    Description
       
    4.1
    Second Amendment to Form of Senior Secured Convertible Promissory Note due March 8, 2027.
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document).
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    Date: May 5, 2025
     
      Dyadic International, Inc.
         
      By: /s/ Mark A. Emalfarb
      Name: Mark A. Emalfarb
      Title: Chief Executive Officer
     
     
    Get the next $DYAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DYAI

    DatePrice TargetRatingAnalyst
    10/23/2025$3.00Buy
    H.C. Wainwright
    9/8/2025Buy
    Craig Hallum
    7/18/2022Buy → Neutral
    Dawson James
    12/17/2021$7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DYAI
    SEC Filings

    View All

    SEC Form 8-K filed by Dyadic International Inc.

    8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)

    3/6/26 5:04:30 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by Dyadic International Inc.

    424B5 - DYADIC INTERNATIONAL INC (0001213809) (Filer)

    3/6/26 5:02:34 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Dyadic International Inc.

    SCHEDULE 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

    2/17/26 4:14:24 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

    JUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bioindustrial applications today announced that it has entered into an original equipment manufacturer ("OEM") distribution agreement with Integrated Biotherapeutics, LLC, d/b/a IBT Bioservices ("IBT"), a life sciences reagent manufacturer and distributor serving global research markets. Through this collaboration, Dyadic-produced recombinant protein products will be commercialized through IBT's established sales ch

    3/16/26 7:20:00 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

    NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry. REGISTER AND VIEW PRESENTATIONS HERE The presentations will be available 24/7 for 90 days. Investors,

    3/13/26 8:35:00 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026

    JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the year ended December 31, 2025 and host a corporate update conference call on Wednesday, March 25, 2026. Conference Call Information Date: Wednesday, March 25, 2026 Time: 5:00 p.m. Eastern

    3/11/26 4:10:00 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP of Research and Bus. Dvlpmt Tchelet Ronen was granted 18,064 shares, increasing direct ownership by 55% to 50,897 units (SEC Form 4)

    4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

    1/6/26 6:12:29 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Rawson Ping Wang was granted 29,158 shares, increasing direct ownership by 21% to 170,151 units (SEC Form 4)

    4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

    1/6/26 6:11:42 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Lucy Patrick K. converted options into 21,552 shares, increasing direct ownership by 42% to 72,311 units (SEC Form 4)

    4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

    1/6/26 6:10:38 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and COO Hazelton Joseph P bought $24,700 worth of shares (26,000 units at $0.95), increasing direct ownership by 20% to 155,340 units (SEC Form 4)

    4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

    8/5/25 5:00:10 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Dyadic International with a new price target

    H.C. Wainwright resumed coverage of Dyadic International with a rating of Buy and set a new price target of $3.00

    10/23/25 7:06:50 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Craig Hallum initiated coverage on Dyadic International

    Craig Hallum initiated coverage of Dyadic International with a rating of Buy

    9/8/25 8:52:07 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic International downgraded by Dawson James

    Dawson James downgraded Dyadic International from Buy to Neutral

    7/18/22 9:59:51 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Leadership Updates

    Live Leadership Updates

    View All

    Dyadic Appoints Doug Pace to Its Executive Leadership Team

    JUPITER, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced the appointment of Doug Pace as Executive Vice President of Business Development. The expansion of Dyadic's management team is in response to the increased interest in the Company's microbial platforms, specifically the C1 technology for infectious disease and

    10/9/23 8:30:00 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic Appoints Chief Business Officer to Executive Leadership Team

    JUPITER, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, therapeutics and other protein based products today announced the appointment of Joe Hazelton as Chief Business Officer, effective immediately. The creation of this role supports the global commercialization of the Company's new and existing business initiatives, including corporate strategy, business and corporate develo

    11/9/21 8:30:00 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Financials

    Live finance-specific insights

    View All

    Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026

    JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the year ended December 31, 2025 and host a corporate update conference call on Wednesday, March 25, 2026. Conference Call Information Date: Wednesday, March 25, 2026 Time: 5:00 p.m. Eastern

    3/11/26 4:10:00 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025

    JUPITER, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the second quarter 2025 and host a corporate update conference call on Wednesday, November 12, 2025. Conference Call Information Date: Wednesday, November 12, 2025 Time: 5:00 p.m. Eastern Tim

    10/29/25 7:25:00 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

    JUPITER, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the second quarter 2025 and host a corporate update conference call on Wednesday, August 13, 2025. Conference Call Information Date: Wednesday, August 13, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-

    8/5/25 4:11:35 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DYAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

    SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

    2/13/24 4:41:59 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

    SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

    2/1/24 4:15:18 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

    SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

    3/14/23 4:01:06 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care